Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Cetuximab in Elderly/Frail mCRC
NCT00251186Phase 2Terminated
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Apr 2006
- Primary completion
- Apr 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Response Rate (CR/PR). Started Apr 2006; status: terminated.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00251186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251186.